2021
DOI: 10.1101/2021.07.03.451023
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals

Abstract: The efficacy and safety of a chemotherapy regimen fundamentally depends on its pharmacokinetics. This is currently measured based on blood samples, but the abnormal vasculature and physiological heterogeneity of the tumor microenvironment can produce radically different drug pharmacokinetics relative to the systemic circulation. We have developed an implantable microelectrode array sensor that can collect such tissue-based pharmacokinetic data by simultaneously measuring intratumoral pharmacokinetics from mult… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
3
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 52 publications
1
3
0
Order By: Relevance
“…Figure 3Bi and fig. S8C show that the in-skin measurements stayed within ~80% of the initial measurement values for over 5 hours of operation [comparable to previously reported results in a similar context ( 49 )]. Furthermore, comparison of the biosensor’s response to tobramycin (10 μM) before versus after the biofouling test revealed a statistically nonsignificant effect on the biosensor response ( P = 0.23 in Fig.…”
Section: Resultssupporting
confidence: 86%
See 1 more Smart Citation
“…Figure 3Bi and fig. S8C show that the in-skin measurements stayed within ~80% of the initial measurement values for over 5 hours of operation [comparable to previously reported results in a similar context ( 49 )]. Furthermore, comparison of the biosensor’s response to tobramycin (10 μM) before versus after the biofouling test revealed a statistically nonsignificant effect on the biosensor response ( P = 0.23 in Fig.…”
Section: Resultssupporting
confidence: 86%
“…Furthermore, existing commercial wearable packaging/system integration solutions can be adopted to form a fully integrated wireless patch, given that our patch is compact (~6 mm in diameter) and light (0.5 g) and, in principle, requires the same grade of electronics for wireless operation as those used in commercial solutions (e.g., continuous glucose monitoring devices). The technology could particularly benefit from surface engineering methods ( 49 ), differential/auxiliary measurement techniques ( 18 ), and corrective algorithms that minimize error caused by ISF-specific confounding factors (e.g., biofouling-induced drift within a tissue environment). Furthermore, standard microneedle sensor calibration methodologies are needed to benchmark the biosensor performance in the ISF environment.…”
Section: Discussionmentioning
confidence: 99%
“…wire and introduced using an intravenous catheter 10,11 ; only limited examples have been reported in which, as is true for continuous glucose monitors 12 , such devices have been adapted to microneedles suitable for performing measurements in the dermis 13 . And while these demonstrations represent a significant advance in in vivo molecular monitoring, all prior reports have been limited to rats, the overwhelming majority of which were anesthetized during study.…”
Section: Introductionmentioning
confidence: 99%
“…More recently, "real-time biosensors" [5][6][7][8][9][10] that can continuously measure target concentrations have demonstrated promise as a powerful tool for biomedical applications such as drug dosing [11][12][13][14][15][16][17][18][19][20] , diagnostics [21][22][23] and fundamental research 24 . In contrast with endpoint sensors, real-time sensors must adequately balance the tradeoff between thermodynamics and kinetics.…”
Section: Introductionmentioning
confidence: 99%